Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03251118 · ClinicalTrials.gov registry record
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
A clinical trial of Ulcerative Colitis and Crohn's Disease, sponsored by Target PharmaSolutions.
- Active
- Registry status
- 15,000
- Enrollment target
- 20
- Study locations
NCT03251118: Active study of Ulcerative Colitis and Crohn's Disease, sponsored by Target PharmaSolutions.
NCT03251118 is a study of Ulcerative Colitis and Crohn's Disease that is active but no longer recruiting, run by Target PharmaSolutions. The registered enrollment target is 15,000 participants, above the 1,934-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (676% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03251118, a study of Ulcerative Colitis and Crohn's Disease, is active but no longer recruiting, sponsored by Target PharmaSolutions.
- ACTIVE NOT RECRUITING
- Registry status
- 15,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
TARGET-IBD is a 5-year, longitudinal, observational study of adult and pediatric patients (age 2 and above) being managed for Inflammatory Bowel Disease (IBD) in usual clinical practice. TARGET-IBD will create a research registry of patients with IBD within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Conditions Studied
Study Locations (20)
California
- Om Research - Lancaster
- FACEY Medical Foundation - Mission Hills
- University of California - Davis - Sacramento
- Stanford University - Stanford
Florida
- Gastro Florida - Clearwater
- University of Florida Health Jacksonville-Gastroenterology - Jacksonville
- Advanced Gastroenterology Associates, LLC - Palm Harbor
Louisiana
- Gastroenterology Associates - Baton Rouge
- Louisiana Research Center, LLC - Shreveport
Colorado
- University of Colorado Denver - Aurora
Georgia
- Atlanta Gastro - Atlanta
Illinois
- The University of Chicago Medical Center - Chicago
Indiana
- Indianapolis Gastroenterology Research Foundation - Indianapolis
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15,000 participants |
| Start Date | 2017-07-24 |
| Est. Completion | 2027-03 |
What the registry record for NCT03251118 still lists
NCT03251118 is an observational study that tracks outcomes without assigning an intervention. Its 15,000 participants enrollment target places it among the larger protocols in the corpus, above the 1,934-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (676% higher).
The record links to 4 conditions, with Ulcerative Colitis appearing as the primary indexed condition, and to 0 interventions.
NCT03251118 names 20 study sites across 14 states, led by California, Florida, Louisiana.
Frequently Asked Questions
What is clinical trial NCT03251118 about?
NCT03251118 is a clinical study titled "A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease". TARGET-IBD is a 5-year, longitudinal, observational study of adult and pediatric patients (age 2 and above) being managed for Inflammatory Bowel Disease (IBD) in usual clinical practice. TARGET-IBD will create a research registry of patients with IBD within academic and community real-world practice...
What is the current status of trial NCT03251118?
This trial is currently active not recruiting. The enrollment target is 15,000 participants. The study started on 2017-07-24. Estimated completion is 2027-03.
What conditions does trial NCT03251118 study?
This clinical trial studies the following conditions: Ulcerative Colitis, Crohn's Disease, Inflammatory Bowel Diseases, Indeterminate Colitis.
Who is sponsoring clinical trial NCT03251118?
This trial is sponsored by Target PharmaSolutions, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03251118 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03251118's enrollment target sits among peer trials
15,000 2nd of 122 the highest of 122 other Ulcerative Colitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ulcerative Colitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
RECRUITING · Phase 2
-
Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention
RECRUITING
-
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
RECRUITING · NA
-
A Study of Endoscopic Sleeve Gastroplasty for Obesity in Ulcerative Colitis
RECRUITING · NA
-
Registry and Biorepository for IBD in Central Texas
RECRUITING
-
Nicotinamide Riboside in Ulcerative Colitis
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00857922 · 15,000 participants
Neurosciences Research Repository
- NCT01137643 · 15,000 participants
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
- NCT01550575 · 15,000 participants
Patient Retrospective Outcomes (PRO)
- NCT02253251 · 15,000 participants
Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI